Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01776567




Registration number
NCT01776567
Ethics application status
Date submitted
11/08/2012
Date registered
28/01/2013
Date last updated
5/08/2014

Titles & IDs
Public title
Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms
Scientific title
Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms.
Secondary ID [1] 0 0
01/12
Universal Trial Number (UTN)
Trial acronym
APPOSE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Coronary Artery Disease 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Everolimus eluting stents

Active Comparator: Cobalt Chromium Everolimus-eluting stent (Xience Prime) - Cobalt Chromium Everolimus-eluting stent (Xience Prime)

Active Comparator: Platinum Chromium Everolimus-eluting stent (Promus Element) - Platinum Chromium Everolimus-eluting stent (Promus Element)


Treatment: Devices: Everolimus eluting stents
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
• Percent incomplete stent apposition using OCT of the CoCr-EES versus the PtCr-EES stent inflated to nominal pressure and following optimal post-dilatation. Stent length (mm) at implantation following nominal pressure and following post-dilatation
Timepoint [1] 0 0
Immediately following stent deployment
Secondary outcome [1] 0 0
Percentage of uncovered stent struts
Timepoint [1] 0 0
6 mths post initial PCI procedure
Secondary outcome [2] 0 0
Mean neointimal tissue thickness (microns)
Timepoint [2] 0 0
6 months post initial PCI Procedure
Secondary outcome [3] 0 0
Stent length (mm) measured using OCT
Timepoint [3] 0 0
6 months post initial PCI procedure

Eligibility
Key inclusion criteria
1. Age = 18 years

2. Symptomatic coronary artery disease including patients with chronic stable angina,
silent ischemia, and acute coronary syndromes including non-ST elevation myocardial
infarction

3. Presence of one or more coronary artery stenosis > 50% in a native coronary artery
with a reference diameter ranging from 2.25 to 4.25 mm which can be covered with one
or multiple stents

4. No limitation to the number of treated lesions or number of vessels according to the
randomization group

5. De-novo native coronary disease with complex lesions involving: Bifurcations, chronic
occlusions > 3 months, lesions > 20mm in length or moderately/heavily calcified
lesions of any length
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Known intolerance to aspirin, clopidogrel, heparin, cobalt chromium, platinum
chromium, everolimus, contrast material

2. Acute ST-segment elevation myocardial infarction

3. Type A lesion including vessel angulation <45 degrees

4. Bypass graft

5. Inability to provide informed consent

6. Pregnancy

7. Planned surgery within 12 months of PCI unless dual antiplatelet therapy is maintained
throughout the peri-surgical period

8. Left ventricular ejection fraction < 25%

9. Serum creatinine > 180mmol/L

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Unknown status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2015
Actual
Sample size
Target
60
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Concord Repatriation Hospital - Concord
Recruitment hospital [2] 0 0
The Prince Charles Hospital - Brisbane
Recruitment hospital [3] 0 0
Northern Hospital - Epping
Recruitment hospital [4] 0 0
St Vincent's Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
- Concord
Recruitment postcode(s) [2] 0 0
- Brisbane
Recruitment postcode(s) [3] 0 0
3076 - Epping
Recruitment postcode(s) [4] 0 0
3065 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Northern Hospital, Australia
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Abbott Medical Devices
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the trial is to directly compare the Cobalt Chromium platform
everolimus-eluting stent, Xience Prime™, with the Platinum Chromium platform
everolimus-eluting stent, Promus Element™, in relation to stent scaffolding shape, position
with the heart blood vessel and extent of tissue coverage (at 6 months) using optical
coherence tomography.

Hypotheses:

1. The alloy composition and strut design of a drug-eluting stent has a direct bearing on
stent apposition measured using OCT.

2. Stent design and alloy composition have a direct influence on radial support and
scaffold shrinkage.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01776567
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Peter Barlis
Address 0 0
Northern Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Peter Barlis, MBBS MPH PHD FESC FRACP
Address 0 0
Country 0 0
Phone 0 0
+61 3 8405 8554
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01776567